News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IntelliCell BioSciences (SVFC) Announces It Will File An IND For Osteoarthritis Of The Knee In Conjunction With The Andrews's Research And Educational Foundation


3/17/2014 10:47:10 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, NY--(Marketwired - March 17, 2014) - IntelliCell Biosciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has signed consulting agreements with Dr Adam Anz and Dr Josh Hackel of the Andrews's Research and Education Foundation (AREF) in Gulf Breeze, Florida. Intellicell will be filing an IND for the treatment of osteoarthritis of knee lead by Dr. James Andrews and conducted by Drs. Anz and Hackel for its Stromal Vascular Fraction Cells (SVFC).

IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "I am excited that the company will be filing its first IND for osteoarthritis of the knee and has the honor to be working with Dr. Andrews, Dr. Anz and Dr. Hackel. They are the some of the most prominent sports medicine physicians in the company. Dr. Anz and Dr. Hackel bring their vast knowledge and experience in stem cells to this project. With this distinguished group of doctors on board we will be able to advance the research and science of the SVF cellular product in the fields of orthopedic and sports medicine."

As said by Dr. Adam Anz, "Dr. Victor, through Intellicell Biosciences, has been a pioneer in the clinical application of stem cell therapy in the United States. His interactions with the FDA have helped us understand the current regulatory status, and he has a practice, which recently has passed their scrutiny. At the Andrews Research and Education Institute, we look forward to collaborating with him and to applying his technology in a compliant fashion. Working together we will produce evidence about the value of stem cell therapy for the treatment of joint injuries and degeneration, which will help us treat our patients better."

According to Dr. Josh Hackel, "We have recognized IntelliCell BioSciences as a forward thinking company and we are excited to continue FDA compliant research in this area as it relates to sports medicine and the treatment of our patients. It will be research like this at the Andrews Research and Education Institute in collaboration with IntelliCell BioSciences that will further our understanding and improve our management of sports medicine injuries."

About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

About Dr. James Andrews
Dr. James Andrews is internationally known and recognized for his scientific and clinical research contributions in knee, shoulder and elbow injuries, as well as his skill as an orthopedic surgeon. Dr. Andrews is a founding partner and medical director for the Andrews Institute in Gulf Breeze, Florida. In addition, he is a founding member of the American Sports Medicine Institute (ASMI).

Dr. Andrews has been the mentor for more than 250 orthopedic/sports medicine fellows and more than 45 primary care sports medicine fellows. Involved in education and research in sports medicine and orthopedic surgery, he has made major presentations on every continent, and has authored numerous scientific articles and books.

About Dr. Adam Anz
Adam Williams Anz, M.D., is a fellowship trained orthopedic surgeon who specializes in sports related injuries, specifically focusing on complex knee surgery, hip arthroscopy, and innovative stem cell treatments. He has many peer-reviewed publications and presentations with a special interest in cartilage regeneration. His main goal is to keep patients of all ages as active as possible in the least invasive way possible.

He completed his orthopedic surgery residency training at Wake Forest University in Winston-Salem, North Carolina where he worked extensively with the Wake Forest Demon Deacons Football team. After residency, he completed a sports fellowship at the world-renowned Steadman Clinic in Vail, Colorado where he learned complex knee surgery from the famed Drs. Steadman and Laprade and hip arthroscopy from Dr. Philippon.

Dr. Anz has numerous orthopedic journal publications and a strong interest in research with projects including the use of CT 3-D reconstruction for subtle hip deformities and a biomechanical project involving MLB pitchers with elbow injury. Dr. Anz's strongest research interest is in cartilage regeneration. During residency he spent 3 weeks in Malaysia with Dr. Khay Yong Saw, an orthopedic surgeon who has pioneered a method to regenerate cartilage using a patient's own stem cells. He returned to Malaysia after his time at the Steadman Clinic for a stem cell fellowship and to work on preparing an application to the FDA in order to apply this cutting edge stem cell technology within the United States.

About Dr. Josh Hackel
Dr. Joshua Hackel, a sports medicine physician, specializes in the prevention, diagnosis, and conservative management of musculoskeletal injuries utilizing the latest medical techniques for anyone who is injured on the job or at home, a weekend warrior, professional, high school or recreational athlete.

Following his residency in 2003 in Family Practice at Columbus Regional Medical Center in Columbus, GA, Dr. Hackel accepted a fellowship at the American Sports Medicine Institute (ASMI) in Primary Care Sports Medicine under the direction of orthopedic surgeon Dr. James R. Andrews. Upon completion of the fellowship he was invited to become a member of the Andrews Orthopedic & Sports Medicine Center in Gulf Breeze, FL.

Dr. Hackel treats acute and chronic musculoskeletal injuries such as joint sprains, strains, knee, hip, elbow, foot, ankle and shoulder injuries, fractures and stress fractures, arthritis/degenerative joint disease, athletes with chronic or acute illnesses, and nutrition.

Dr. Hackel has a multitude of team physician experience in many different sport and recreational arenas. These include team physician for the University of West Florida, Troy University football, Birmingham Barons baseball (AA affiliate of the Chicago White Sox), Birmingham Power of the WNBA, Arena Football's Birmingham Steeldogs, Southeastern Conference (SEC) womenÂ's basketball tournament, Mercedes Olympic Marathon, and the Medical Director for the Pensacola Marathon.

Dr. Hackel practices in Gulf Breeze at the Andrews Orthopedic & Sports Medicine Center and serves as an Associate Clinical Professor of Medicine at Florida State School of Medicine.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.


Contact:
IntelliCell BioSciences, Inc.
Investor Relations
Anna Rhodes
Email Contact
(646) 576-8308

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES